Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 49

1.

Excess α-synuclein compromises phagocytosis in iPSC-derived macrophages.

Haenseler W, Zambon F, Lee H, Vowles J, Rinaldi F, Duggal G, Houlden H, Gwinn K, Wray S, Luk KC, Wade-Martins R, James WS, Cowley SA.

Sci Rep. 2017 Aug 21;7(1):9003. doi: 10.1038/s41598-017-09362-3.

2.

Cell replacement therapy is the remedial solution for treating Parkinson's disease.

Dhivya V, Balachandar V.

Stem Cell Investig. 2017 Jun 30;4:59. doi: 10.21037/sci.2017.06.08. eCollection 2017. Review.

3.

What if it was easier to prevent schizophrenia than to treat it?

J Brennand K.

NPJ Schizophr. 2017 Feb 13;3:9. doi: 10.1038/s41537-017-0012-x. eCollection 2017. No abstract available.

4.

Structural variants in SNCA gene and the implication to synucleinopathies.

Chiba-Falek O.

Curr Opin Genet Dev. 2017 Jun;44:110-116. doi: 10.1016/j.gde.2017.01.014. Epub 2017 Mar 2. Review.

PMID:
28319736
5.

Generation of Cholinergic and Dopaminergic Interneurons from Human Pluripotent Stem Cells as a Relevant Tool for In Vitro Modeling of Neurological Disorders Pathology and Therapy.

Ochalek A, Szczesna K, Petazzi P, Kobolak J, Dinnyes A.

Stem Cells Int. 2016;2016:5838934. doi: 10.1155/2016/5838934. Epub 2016 Dec 25. Review.

6.
7.

Utility of Induced Pluripotent Stem Cells for the Study and Treatment of Genetic Diseases: Focus on Childhood Neurological Disorders.

Barral S, Kurian MA.

Front Mol Neurosci. 2016 Sep 6;9:78. doi: 10.3389/fnmol.2016.00078. eCollection 2016. Review.

8.

Utility of Lymphoblastoid Cell Lines for Induced Pluripotent Stem Cell Generation.

Kumar S, Curran JE, Glahn DC, Blangero J.

Stem Cells Int. 2016;2016:2349261. doi: 10.1155/2016/2349261. Epub 2016 Jun 7.

9.

Induced pluripotent stem cells for modeling and cell therapy of Parkinson's disease.

Csöbönyeiová M, Danišovič Ľ, Polák Š.

Neural Regen Res. 2016 May;11(5):727-8. doi: 10.4103/1673-5374.182692. No abstract available.

10.

Modeling Alzheimer's Disease with Induced Pluripotent Stem Cells: Current Challenges and Future Concerns.

Zhang W, Jiao B, Zhou M, Zhou T, Shen L.

Stem Cells Int. 2016;2016:7828049. doi: 10.1155/2016/7828049. Epub 2016 May 24. Review.

11.

Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.

Momcilovic O, Sivapatham R, Oron TR, Meyer M, Mooney S, Rao MS, Zeng X.

PLoS One. 2016 May 18;11(5):e0154890. doi: 10.1371/journal.pone.0154890. eCollection 2016.

12.

Quantification of dopaminergic neuron differentiation and neurotoxicity via a genetic reporter.

Cui J, Rothstein M, Bennett T, Zhang P, Xia N, Reijo Pera RA.

Sci Rep. 2016 Apr 28;6:25181. doi: 10.1038/srep25181.

13.

Up-regulation of SNCA gene expression: implications to synucleinopathies.

Tagliafierro L, Chiba-Falek O.

Neurogenetics. 2016 Jul;17(3):145-57. doi: 10.1007/s10048-016-0478-0. Epub 2016 Mar 7. Review.

14.

The Application of Human iPSCs in Neurological Diseases: From Bench to Bedside.

Xie N, Tang B.

Stem Cells Int. 2016;2016:6484713. doi: 10.1155/2016/6484713. Epub 2016 Jan 6. Review.

15.

The Progress of Induced Pluripotent Stem Cells as Models of Parkinson's Disease.

Kang JF, Tang BS, Guo JF.

Stem Cells Int. 2016;2016:4126214. doi: 10.1155/2016/4126214. Epub 2016 Jan 6. Review.

16.

An Overview of Direct Somatic Reprogramming: The Ins and Outs of iPSCs.

Menon S, Shailendra S, Renda A, Longaker M, Quarto N.

Int J Mol Sci. 2016 Jan 21;17(1). pii: E141. doi: 10.3390/ijms17010141. Review.

17.

Induced pluripotent stem cells for modeling neurological disorders.

Russo FB, Cugola FR, Fernandes IR, Pignatari GC, Beltrão-Braga PC.

World J Transplant. 2015 Dec 24;5(4):209-21. doi: 10.5500/wjt.v5.i4.209. Review.

18.

Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models.

Fernández-Santiago R, Ezquerra M.

Stem Cells Int. 2016;2016:9464591. doi: 10.1155/2016/9464591. Epub 2015 Nov 30. Review.

19.

Elevated α-synuclein caused by SNCA gene triplication impairs neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent stem cells.

Oliveira LM, Falomir-Lockhart LJ, Botelho MG, Lin KH, Wales P, Koch JC, Gerhardt E, Taschenberger H, Outeiro TF, Lingor P, Schüle B, Arndt-Jovin DJ, Jovin TM.

Cell Death Dis. 2015 Nov 26;6:e1994. doi: 10.1038/cddis.2015.318.

20.

Back and forth in time: Directing age in iPSC-derived lineages.

Cornacchia D, Studer L.

Brain Res. 2017 Feb 1;1656:14-26. doi: 10.1016/j.brainres.2015.11.013. Epub 2015 Nov 17. Review.

PMID:
26592774

Supplemental Content

Support Center